NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869

RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Alectinib

Countries: China

This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically-confirmed stage II-IIIA or selected IIIB (T3N2) NSCLC as per the American Joint Committee on Cancer and International Union Against Cancer (UICC/AJCC), 8th edition
* ALK positive
* Postoperative NSCLC patients who have undergone complete resection
* Had taken Alectinib monotherapy without prior systemic therapy (including other ALK-TKIs or chemotherapy) as adjuvant† therapy for resected stage II-IIIB ALKpositive NSCLC and the time from the first dose to enrollment was no more than 28 days

Exclusion Criteria:

* Patients participating in interventional study of adjuvant treatment
* Pregnant, lactating, or breastfeeding women

Locations (44)

Zhanjiang, Guangdong, China
Guangzhou, Guangzhou, China
Kaifeng, Henan, China
Zhengzhou, Henan, China
Ürümqi, Xinjiang, China
Beijing, China
Beijing, China
Changsha, China
Changzhou, China
Chengdu, China
Chongqing, China
Dalian, China
Fuzhou, China
Guangzhou, China
Hangzhou, China
Hangzhou, China
Harbin, China
Hefei, China
Huzhou, China
Jiangmen, China
Jinan, China
Lanzhou, China
Nanchang, China
Nanjing, China
Nanjing, China
Nanjing, China
Nantong, China
Ningbo, China
Shanghai, China
Shanghai, China
+ 14 more on CT.gov